Technology-Enabled Clinical Trials: Transforming Medical Evidence Generation.


Journal

Circulation
ISSN: 1524-4539
Titre abrégé: Circulation
Pays: United States
ID NLM: 0147763

Informations de publication

Date de publication:
22 10 2019
Historique:
entrez: 22 10 2019
pubmed: 22 10 2019
medline: 18 6 2020
Statut: ppublish

Résumé

The complexity and costs associated with traditional randomized, controlled trials have increased exponentially over time, and now threaten to stifle the development of new drugs and devices. Nevertheless, the growing use of electronic health records, mobile applications, and wearable devices offers significant promise for transforming clinical trials, making them more pragmatic and efficient. However, many challenges must be overcome before these innovations can be implemented routinely in randomized, controlled trial operations. In October of 2018, a diverse stakeholder group convened in Washington, DC, to examine how electronic health record, mobile, and wearable technologies could be applied to clinical trials. The group specifically examined how these technologies might streamline the execution of clinical trial components, delineated innovative trial designs facilitated by technological developments, identified barriers to implementation, and determined the optimal frameworks needed for regulatory oversight. The group concluded that the application of novel technologies to clinical trials provided enormous potential, yet these changes needed to be iterative and facilitated by continuous learning and pilot studies.

Identifiants

pubmed: 31634011
doi: 10.1161/CIRCULATIONAHA.119.040798
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

1426-1436

Auteurs

Guillaume Marquis-Gravel (G)

Duke Clinical Research Institute, Durham, NC (G.M.-G., M.T.R., B.P.-L., E.D.P.).

Matthew T Roe (MT)

Duke Clinical Research Institute, Durham, NC (G.M.-G., M.T.R., B.P.-L., E.D.P.).

Mintu P Turakhia (MP)

Center for Digital Health (M.P.T.), Stanford University, CA.
VA Palo Alto Health Care System, CA (M.P.T.).

William Boden (W)

Boston University and VA New England Health Care System, MA (W.B.).

Robert Temple (R)

U.S. Food and Drug Administration, Silver Spring, MD (R.T., N.S.).

Abhinav Sharma (A)

Division of Cardiology (A.S.), Stanford University, CA.
Division of Cardiology, McGill University Health Centre, Montreal, QC, Canada (A.S.).

Boaz Hirshberg (B)

MedImmune, Gaithersburg, MD (B.H.).

Paul Slater (P)

Life Sciences Innovation, Microsoft, Seattle, WA (P.S.).

Noah Craft (N)

Science 37 Inc, Los Angeles, CA (N.C.).

Norman Stockbridge (N)

U.S. Food and Drug Administration, Silver Spring, MD (R.T., N.S.).

Bryan McDowell (B)

Novartis Pharma AG, Rotkreuz, Switzerland (B.M.).

Joanne Waldstreicher (J)

Johnson & Johnson, New Brunswick, NJ (J.W.).

Ariel Bourla (A)

Flatiron Health, New York (A.B.).

Sameer Bansilal (S)

Bayer U.S. LLC Pharmaceuticals, Whippany, NJ (S.B.).

Jennifer L Wong (JL)

AstraZeneca, Gaithersburg, MD (J.L.W.).

Claire Meunier (C)

Evidation Health, San Mateo, CA (C.M.).

Helina Kassahun (H)

Amgen Inc, Thousand Oaks, CA (H.K.).

Philip Coran (P)

Medidata, New York (P.C.).

Lauren Bataille (L)

The Michael J. Fox Foundation for Parkinson's Research, New York (L.B.).

Bray Patrick-Lake (B)

Duke Clinical Research Institute, Durham, NC (G.M.-G., M.T.R., B.P.-L., E.D.P.).

Brad Hirsch (B)

SignalPath, Raleigh, NC (B.H.).

John Reites (J)

THREAD, Tustin, CA (J.R.).

Rajesh Mehta (R)

Healthagen Outcomes, New York (R.M.).

Evan D Muse (ED)

Scripps Research Translational Institute; Division of Cardiovascular Disease, Scripps Clinic, Scripps Health, La Jolla, CA (E.D.M.).

Karen J Chandross (KJ)

Sanofi R&D, Bridgewater, NJ (K.J.C.).

Jonathan C Silverstein (JC)

University of Pittsburgh, PA (J.C.S.).

Christina Silcox (C)

Duke-Margolis Center for Health Policy, Washington, DC (C.S.).

J Marc Overhage (JM)

Cerner Corporation, Kansas City, MO (J.M.O.).

Robert M Califf (RM)

Department of Medicine (R.M.C.), Stanford University, CA.
Duke Forge, Duke University School of Medicine, Durham, NC (R.M.C.).
Verily Life Sciences (Alphabet), South San Francisco, CA (R.M.C.).

Eric D Peterson (ED)

Duke Clinical Research Institute, Durham, NC (G.M.-G., M.T.R., B.P.-L., E.D.P.).

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH